Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

682 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Reduced intensity versus myeloablative conditioning for MDS: long-term results of an EBMT phase III study (RICMAC).
Niederwieser C, Iacobelli S, Franke GN, Koster L, van Os M, Platzbecker U, Hübel K, Scheid C, Müller LP, Stelljes M, Morozova E, Passweg J, Onida F, Dreger P, Saccardi R, Ladetto M, Salmenniemi U, Bethge W, Poiré X, Kobbe G, McLornan DP, Robin M, Kröger N. Niederwieser C, et al. Among authors: passweg j. Bone Marrow Transplant. 2024 Apr 25. doi: 10.1038/s41409-024-02282-7. Online ahead of print. Bone Marrow Transplant. 2024. PMID: 38664589
High-dose chemotherapy using BEAM for tumor debulking without stem cell support followed by early allogeneic reduced intensity conditioning transplantation to induce a graft-versus-lymphoma effect in patients with high risk or refractory lymphoma.
Buser AS, Heim D, Bucher C, Tichelli A, Gratwohl A, Passweg JR. Buser AS, et al. Among authors: passweg jr. Bone Marrow Transplant. 2004 May;33(10):1011-4. doi: 10.1038/sj.bmt.1704489. Bone Marrow Transplant. 2004. PMID: 15064693 Clinical Trial.
High-dose chemotherapy using BEAM without autologous rescue followed by reduced-intensity conditioning allogeneic stem-cell transplantation for refractory or relapsing lymphomas: a comparison of delayed versus immediate transplantation.
Buser AS, Stern M, Bucher C, Arber C, Heim D, Halter J, Meyer-Monard S, Stussi G, Lohri A, Ghielmini M, Tichelli A, Passweg JR, Gratwohl A. Buser AS, et al. Among authors: passweg jr. Bone Marrow Transplant. 2007 Mar;39(6):335-40. doi: 10.1038/sj.bmt.1705597. Bone Marrow Transplant. 2007. PMID: 17342158 Clinical Trial.
Outcome of patients developing GVHD after DLI given to treat CML relapse: a study by the Chronic Leukemia Working Party of the EBMT.
Chalandon Y, Passweg JR, Schmid C, Olavarria E, Dazzi F, Simula MP, Ljungman P, Schattenberg A, de Witte T, Lenhoff S, Jacobs P, Volin L, Iacobelli S, Finke J, Niederwieser D, Guglielmi C; Chronic Leukemia Working Party of European Group for Blood and Marrow Transplantation. Chalandon Y, et al. Among authors: passweg jr. Bone Marrow Transplant. 2010 Mar;45(3):558-64. doi: 10.1038/bmt.2009.177. Epub 2009 Jul 27. Bone Marrow Transplant. 2010. PMID: 19633691
Stem cell transplantation for patients with Evans syndrome.
Benesch M, Urban C, Platzbecker U, Passweg J. Benesch M, et al. Among authors: passweg j. Expert Rev Clin Immunol. 2009 May;5(3):341-8. doi: 10.1586/eci.09.9. Expert Rev Clin Immunol. 2009. PMID: 20477011
682 results